Gain Therapeutics, Inc. (GANX)

NASDAQ: GANX · IEX Real-Time Price · USD
4.680
+0.190 (4.23%)
Mar 1, 2024, 4:00 PM EST - Market closed
4.23%
Market Cap 75.81M
Revenue (ttm) 55,180
Net Income (ttm) -22.22M
Shares Out 20.46M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 103,245
Open 4.640
Previous Close 4.490
Day's Range 4.520 - 4.700
52-Week Range 2.000 - 6.190
Beta 0.39
Analysts Strong Buy
Price Target 8.75 (+86.97%)
Earnings Date Mar 21, 2024

About GANX

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 18, 2021
Employees 28
Stock Exchange NASDAQ
Ticker Symbol GANX
Full Company Profile

Financial Performance

In 2022, GANX's revenue was $140,108, a decrease of -15.08% compared to the previous year's $164,994. Losses were -$17.59 million, 26.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price forecast is $8.75, which is an increase of 86.97% from the latest price.

Price Target
$8.75
(86.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

5 days ago - GlobeNewsWire

Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co....

18 days ago - GlobeNewsWire

UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm Data presented at 20th WORLDSym...

26 days ago - GlobeNewsWire

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Presentation will highlight new data of GT-02287 in preclinical models of Parkinson's disease Presentation will highlight new data of GT-02287 in preclinical models of Parkinson's disease

2 months ago - GlobeNewsWire

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis

3 months ago - GlobeNewsWire

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of alloste...

3 months ago - GlobeNewsWire

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

BETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing of an underwritten public offering of 2,545,000 shares of ...

3 months ago - GlobeNewsWire

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of 2,213,044 shares of ...

3 months ago - GlobeNewsWire

Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, ...

3 months ago - GlobeNewsWire

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule

3 months ago - GlobeNewsWire

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

First small molecule allosteric binder discovered with Gain's computational drug discovery platform enters clinical development First small molecule allosteric binder discovered with Gain's computatio...

5 months ago - GlobeNewsWire

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allost...

5 months ago - GlobeNewsWire

Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference

BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generati...

5 months ago - GlobeNewsWire

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

First drug candidate identified with Gain's proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase

6 months ago - GlobeNewsWire

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor ...

6 months ago - GlobeNewsWire

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson's Disease...

7 months ago - GlobeNewsWire

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson's Disease and Movement Disorders®

BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation of allosteric small molec...

7 months ago - GlobeNewsWire

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

BETHESDA, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small mo...

7 months ago - GlobeNewsWire

Gain Therapeutics to Present at the Jefferies Healthcare Conference

BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small mo...

9 months ago - GlobeNewsWire

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

BETHESDA, Md., May 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small mol...

10 months ago - GlobeNewsWire

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease

BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today anno...

10 months ago - GlobeNewsWire

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small m...

11 months ago - GlobeNewsWire

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease Study results support the disease-modifying poten...

1 year ago - GlobeNewsWire

Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

BETHESDA, Md., March 23, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small m...

1 year ago - GlobeNewsWire

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March ...

1 year ago - GlobeNewsWire